Teva Pharmaceutical Industries Limited (TEV) - Total Assets
Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEV) holds total assets worth €39.86 Billion EUR as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Teva Pharmaceutical Industries Limited - Total Assets Trend (2015–2024)
This chart illustrates how Teva Pharmaceutical Industries Limited's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Teva Pharmaceutical Industries Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Teva Pharmaceutical Industries Limited's total assets of €39.86 Billion consist of 31.9% current assets and 68.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.4% |
| Accounts Receivable | €3.06 Billion | 7.8% |
| Inventory | €3.01 Billion | 7.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.42 Billion | 11.2% |
| Goodwill | €15.15 Billion | 38.5% |
Asset Composition Trend (2015–2024)
This chart illustrates how Teva Pharmaceutical Industries Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Teva Pharmaceutical Industries Limited's current assets represent 31.9% of total assets in 2024, a decrease from 33.9% in 2015.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2024, down from 12.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, unchanged from 49.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 38.5% of total assets.
Teva Pharmaceutical Industries Limited Competitors by Total Assets
Key competitors of Teva Pharmaceutical Industries Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩642.17 Billion |
|
Samil Pharm
KO:000520
|
Korea | ₩375.58 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma Inc
KO:000227
|
Korea | ₩202.42 Billion |
|
Ildong Holdings Co Ltd
KO:000230
|
Korea | ₩813.62 Billion |
Teva Pharmaceutical Industries Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.11 | 0.89 | 0.99 |
| Quick Ratio | 0.82 | 0.61 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.25 Billion | €-1.48 Billion | €-159.00 Million |
Teva Pharmaceutical Industries Limited - Advanced Valuation Insights
This section examines the relationship between Teva Pharmaceutical Industries Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.91 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | -9.6% |
| Total Assets | €39.33 Billion |
| Market Capitalization | $24.98 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Teva Pharmaceutical Industries Limited's assets below their book value (0.64x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Teva Pharmaceutical Industries Limited's assets decreased by 9.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Teva Pharmaceutical Industries Limited (2015–2024)
The table below shows the annual total assets of Teva Pharmaceutical Industries Limited from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €39.33 Billion | -9.55% |
| 2023-12-31 | €43.48 Billion | -1.20% |
| 2022-12-31 | €44.01 Billion | -7.68% |
| 2021-12-31 | €47.67 Billion | -5.87% |
| 2020-12-31 | €50.64 Billion | -11.88% |
| 2019-12-31 | €57.47 Billion | -5.29% |
| 2018-12-31 | €60.68 Billion | -14.07% |
| 2017-12-31 | €70.61 Billion | -23.98% |
| 2016-12-31 | €92.89 Billion | +71.28% |
| 2015-12-31 | €54.23 Billion | -- |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more